Heat Biologics and Adaptive Biotechnologies Corporation have entered an agreement to further develop novel immunotherapies.

Pursuant to the agreement, Heat Biologics’ ImPACT and ComPACT-based immunotherapies will be analysed and characterised using Adaptive Biotechnologies’ ImmunoSEQ, an immune profiling assay.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The agreement enables the two partners to identify significant biomarkers to further develop immunotherapies.

Celsion Corporation and Children’s Research Institute have entered a partnership to develop new treatments for solid tumours in children and young adults.

“Celsion Corporation and Children’s Research Institute have entered a partnership to develop new treatments for solid tumours in children and young adults.”

Under the agreement, the two partners will study the use of ThermoDox in combination with high-intensity focused ultrasound in a Phase I clinical study to treat the relapsed or refractory solid tumours.

The Phase I clinical study will be partly funded by the National institutes of Health.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Cambridge Isotope Laboratories and IROA Technologies have entered an agreement to develop and distribute the latter’s Biochemical Quantitation kits worldwide.

The two partners will develop the kits for metabolic profiling for cell populations and biological samples to overcome the analytical challenges of metabolic analysis.

Accelerated Pharma has announced initial public offering (IPO) of its 1.8 million common stock shares to raise gross proceeds of up to $18.9 million.

Rodman & Renshaw and Maxim Group are acting as joint book runners, while Ellen Grossman & Schole is acting as the legal advisor to the offering.

The company plans to use the funds to advance its Phase II clinical trial for Picoplatin and also to increase the working capital and for other general corporate purposes.

Eris Lifesciences plans to issue its shares in initial public offering (IPO) through ChrysCapital Management Company.

The company expects to raise $300 million from the offering.

Axis Capital, Credit Suisse Securities (India) and Citigroup Global Markets India are the financial advisors for the offering.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact